Navigation Links
Transposagen Creates a Rat Model of the Human Immune System
Date:8/6/2009

LEXINGTON, Ky., Aug. 6 /PRNewswire/ -- Transposagen Biopharmaceuticals, Inc. based in Lexington, KY announced today that its scientists and collaborators from the Medical College of Wisconsin have created and characterized the world's first rat model of severe combined immunodeficiency, or SCID. The Transposagen rat has a nearly complete lack of the major components of the immune system. Transposagen will be marketing SCID rats to pharmaceutical and biotechnology companies. "Transposagen is pleased to have characterized the world's first rat model of SCID. We now have intellectual property covering the SCID phenotype in rat and will be offering the SCID rat and other rat models of the immune system in the near future," said Dr. Eric Ostertag, CEO of Transposagen.

SCID can also affect humans, such as the "Bubble Boy," who had to live inside of a sterile environment to reduce the likelihood of contracting a fatal infection. The SCID mouse has been one of the most often used animal models in the history of drug discovery and development research. Transposagen's SCID rats are characterized by a deficiency of T-cells, B-cells and NK-cells, some of the white blood cells necessary to prevent invasive bacteria and viruses from causing serious disease. "This new immune deficiency rat model cannot reject transplanted tissues, even from other species, and will be especially important in cancer and transplantation research," said Dr. Ostertag.

Rat models are superior to mouse models for testing the pharmacodynamics and toxicity of potential therapeutic compounds. This is partially because the number and type of many of the rat's detoxifying enzymes are very similar to those in humans. Rats are also better models than mice for specific disease categories including human cardiovascular disease, diabetes, arthritis, and many autoimmune, neurological and behavioral disorders.

Transposagen has exclusive worldwide licensing rights to create TKO(TM) Knockout Rat Models using a variety of mobile DNA technologies. Knockout rats are pharmaceutical research models with single gene disruptions that mimic human diseases. Transposagen's goal is to produce 30,000 unique knockout rat lines to represent each gene in the rat genome. Transposagen is also creating a cryo-preserved sperm repository and a tissue bank from all of the knockout rats it produces.

About Transposagen Biopharmaceuticals:

Transposagen Biopharmaceuticals, Inc., a Lexington, KY based company, is the worldwide leader in the creation of unique genetically modified rat models. These models mimic human diseases and are used for drug discovery and development research. The production of animal models for research is a $1.2 billion/year market and the genetically modified animal market is expected to grow 12% annually through 2012. For more information, visit www.transposagenbio.com.

About the Medical College of Wisconsin: The Medical College of Wisconsin in Milwaukee, www.mcw.edu, is a private, freestanding academic institution dedicated to leadership and excellence in advancing the prevention, diagnosis and treatment of disease and injury through education, discovery, patient care and community engagement. A major national research center and academic medical center, its faculty physicians and scientists direct or collaborate on more than 3,000 research studies, publish over 1,300 peer-reviewed scientific papers, and provide care in virtually every specialty of medicine to approximately 350,000 patients annually.

    Contact:
    George Ward
    201 W. Second St.
    Lexington, KY 40507
    gward@transposagenbio.com
    859-428-8561


'/>"/>
SOURCE Transposagen Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Laser technology creates new forms of metal and enhances aircraft performance
2. ParagonRx Creates New Website Featuring REMS Help Center for Pharma
3. A Global View: NanoLogix Creates Science Advisory Board
4. GSK and Pfizer Innovative Agreement Creates Specialist HIV Company
5. Pathway for Biosimilars Act Protects Patients, Promotes Competition, Preserves Innovation and Creates Quality Jobs, Lilly Says
6. MRI Expands Energy Role: Launches Center for Integrated Algal Research and Creates Director of Energy Programs Position
7. New process creates 3-D nanostructures with magnetic materials
8. Monsantos Industry-Leading Seed Position Creates Accelerated Biotech Trait Opportunity in Latin America
9. Inclinix Expansion Creates New Position and Promotions
10. CryoPort Creates Personal Wall on Wallst.nets Financial Social Community, my.wallst.net
11. ADVENTRX Creates Executive Vice President Position and Announces New Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... 11, 2016 Non-profit Consortium Aims to ... to Support Research and Discovery --> ... an ambitious plan to sequence 100,000 individuals. It is intended ... at least 7 of North and East Asian countries. ... phase, the project will focus on creating phased reference genomes ...
(Date:2/11/2016)... Feb. 11, 2016  Spectra BioPharma Selling Solutions (Spectra) ... provides biopharma companies the experience, expertise, operational delivery ... outsourced sales teams. Created in concert with industry ... the strategic and tactical needs of its clients ... through both personal and non-personal promotion. ...
(Date:2/11/2016)... , Feb. 11, 2016   BioInformant ... report, "Stem Cell Research Products, Opportunities, Tools, and Technologies ... ... in the stem cell industry, BioInformant has more than ... the stem cell market, by stem cell type. This ...
(Date:2/10/2016)... Early-career researchers from ... , Uganda and Yemen ... nutrition   Indonesia , Nepal ... Yemen are being honored for their accomplishments in ... celebrated for mentoring young women scientists who are pursuing careers in agriculture, ...
Breaking Biology Technology:
(Date:2/3/2016)... PUNE, India , February 3, 2016 ... to the new market research report "Automated Fingerprint Identification ... (Tenprint Search, Latent Search), Application (Banking & Finance, Government, ... 2020", published by MarketsandMarkets, the market is expected to ... estimated CAGR of 21.0% between 2015 and 2020. The ...
(Date:2/2/2016)... , Feb. 2, 2016  BioMEMS ... are primarily focused on medical screening and ... point-of-care parameters. Wearable devices that facilitate and ... freedom of movement are being bolstered through ... human biomedical signal acquisition coupled with wireless ...
(Date:2/2/2016)... NEW YORK , Feb. 2, 2016 Technology ... service presents an analysis of the digital and computed ... Malaysia , and Indonesia ... current trends and market size, as well as regional ... by country and discusses market penetration and market attractiveness, ...
Breaking Biology News(10 mins):